Ozempic equivalent dose to Mounjaro: how the two medicines compare

Why there is no clean 'Ozempic equivalent' for a Mounjaro dose

The question is reasonable. If you have been on Ozempic for diabetes and your doctor is now discussing tirzepatide, or you have read about Mounjaro and want to understand where a particular dose sits relative to what you already know, wanting a direct comparison makes intuitive sense.

The problem is structural. Ozempic doses run from 0.5 mg to 2 mg weekly. Mounjaro doses run from 2.5 mg to 15 mg weekly. Those numbers are not measuring the same thing on the same scale. The two drugs bind to different receptors, Mounjaro activates both the GIP receptor and the GLP-1 receptor, while semaglutide (Ozempic or Wegovy) targets GLP-1 alone. Because the receptor pathways differ, the amount of drug needed to produce a given effect is not comparable by simple arithmetic.

Clinical trial researchers have compared the medicines head-to-head, and the SURMOUNT-1 results published in the New England Journal of Medicine give context for what tirzepatide achieves at its higher doses, but trial results describe populations, not individuals. For a practical look at how published dose relationships have been mapped, the Ozempic versus Mounjaro dose chart sets the numbers side by side in a format that is easier to read at a glance.

The bottom line is that the comparison requires clinical judgement, not a calculator.

What is Ozempic actually licensed for in the UK, and why does that matter here?

Ozempic (semaglutide 0.5 mg, 1 mg and 2 mg) holds a UK licence for type 2 diabetes management, issued by the MHRA. It is not authorised for weight loss in the UK. This is not a technicality. The NHS medicines page on semaglutide is clear on which formulations are licensed for which purposes, and the MHRA has specifically stated that GLP-1 medicines are not approved for quick or cosmetic weight loss.

Wegovy (the same active ingredient, semaglutide, at 2.4 mg or the newer 7.2 mg dose) is the weight-management-licensed version made by Novo Nordisk. Mounjaro (tirzepatide) is the licensed weight-management option from Eli Lilly. These are the two medicines a UK prescriber can lawfully and appropriately prescribe for weight loss.

So if you have been prescribed Ozempic by a diabetes specialist and are now asking about Mounjaro, the conversation needs to go through your prescriber. And if you have been reading about Ozempic online as a weight-loss option and want to compare it with Mounjaro, the relevant UK comparison is Wegovy versus Mounjaro. The full Wegovy versus Mounjaro comparison covers that properly. For the specific question of how a 1 mg Ozempic dose relates to Mounjaro in the clinical literature, there is also a dedicated look at the Ozempic 1 mg to Mounjaro equivalent.

Understanding the licensing distinction is not pedantry, it shapes every clinical decision made around these medicines.

How do the dose schedules compare on paper?

Even accepting that there is no fixed equivalence, a factual side-by-side of the dose structures helps orient the question.

Sources: NICE technology appraisal TA1026 (tirzepatide); NEJM SURMOUNT-1; MHRA product licences.

The numbers look as though 2.5 mg of Mounjaro should be weaker than 0.5 mg of Ozempic. That reasoning does not hold. The starter dose for tirzepatide is a tolerability step, its function is to let the body adjust, not to deliver maximum effect. The titration schedule runs over months, guided by the prescriber. If you are trying to understand how the two weight-management medicines line up at each stage of treatment, the Mounjaro and Wegovy equivalent doses page works through that carefully, drawing on the published clinical comparisons. For a structured look at how Mounjaro and Wegovy doses map to each other (which is the more clinically meaningful weight-management comparison), the Mounjaro equivalent dose to Wegovy page works through that carefully.

If you are considering a move to Mounjaro, what happens next?

Most people who search this question fall into one of two groups. Either they are currently on Ozempic for diabetes and their care team is discussing tirzepatide, in which case that conversation belongs with their diabetes team or GP, who holds their full history. Or they have encountered Ozempic as a name in weight-loss discussions and are trying to understand where Mounjaro sits relative to it.

For the second group, the practical route is straightforward. Mounjaro and Wegovy are both legally available via private prescription from a registered UK pharmacy, subject to clinical assessment. Neither is available without a prescription. At nume, our clinical team reviews every consultation personally, a named prescriber reads your submission and makes a clinical decision the same day. There is no algorithm standing between your answers and a prescriber's eyes.

If you have been on a semaglutide product previously and want to discuss whether tirzepatide is appropriate, that is exactly the kind of context the consultation captures. Transfer patients provide evidence of their current treatment, and dose decisions are made individually. Questions about how the dose schedules compare between Wegovy and Mounjaro (particularly if you are wondering whether staying on semaglutide for the longer term makes sense) are addressed on the Wegovy maintenance after Mounjaro page.

Which medicine suits you is a clinical decision our prescribers make with you. If you would like to start that conversation, check your eligibility with a free consultation.